This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy.

Please visit clinicaltrials.gov for more information about this study.

Rights

Expected to start in 2020.

Phase IPhase IIPhase III
Phase I
Phase II
Phase III